Find out what TRUXIMA® can do for you - Truxima® (rituximab) is the world's first monoclonal antibody (mAb) biosimilar in oncology ap-proved by the European Medicines Agency(EMA). Truxima® was approved by the EC for the same indications as the reference rituximab, based on data demonstrating comparability in terms of efficacy and safety. Truxima is indicated for the treatment of followings.

Truxima® ▼ is subject to additional monitoring

If you experience any side effects when taking Truxima® ▼ or any other medicine, talk to your doctor, pharmacist or nurse. This includes possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.


  • Non-Hodgkin's Lymphoma
    (NHL)

    Truxima® is approved for the treatment of Non-Hodgkin's Lymphoma (NHL). Truxima can be used as a single agent or in combination with chemotherapy to relieve symptoms of NHL, slow the progression of cancer, and induce/maintain remission
    Learn More
  • Chronic Lymphocytic Leukemia (CLL)

    Truxima® (rituximab) is approved for the treatment of previously treated and untreated Chronic Lymphocytic Leukemia (CLL) as a targeted therapy, to relieve symptoms, prevent cancer progression, and maintain remission.
    Learn More
  • Rheumatoid Arthritis
    (RA)

    Truxima® in combination with methotrexate is approved for the treatment of rheumatoid arthritis in patients who have not responded to previous treatments, including synthetic Disease-Modifying Antirheumatic Drugs (sDMARDs) and Tumour Necrosis Factor (TNF) inhibitors.
    Learn More
  • Granulomatosis with Polyangiitis (GPA)/Microscopic Polyangiitis (MPA)

    Truxima®, in combination with glucocorticoids, is approved for the induction of remission in adult patients with severe, active Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA).
    Learn More